Business Context and Reporting Period
Company: Marker Therapeutics, Inc. (MRKR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: A clinical-stage immuno-oncology company developing Multi-Antigen Recognizing (MAR)-T cell therapies for hematological malignancies and solid tumors. The company has no commercial product revenue and relies on grant income and capital markets for funding.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue (Grant Income) | $1.23M | $1.93M | $2.44M | $4.34M |
| Net Loss | $(2.00M) | $(2.31M) | $(10.46M) | $(6.89M) |
| Net Loss Per Share (Basic/Diluted) | $(0.12) | $(0.26) | $(0.75) | $(0.77) |
| Cash & Restricted Cash (End of Period) | $18.94M | $8.99M | $18.94M | $8.99M |
| Working Capital | $18.39M | $7.45M | $18.39M | $7.45M |
| Operating Cash Flow (9M) | $(10.11M) | $(6.21M) | $(10.11M) | $(6.21M) |
Material Changes vs. Prior Period
- Revenue Decline: Grant income decreased 36% in Q3 2025 compared to Q3 2024, and 44% on a year-to-date basis, primarily due to the recognition timing of specific grants (CPRIT, NIH SBIR).
- Expense Volatility:
- Q3: Total operating expenses decreased 22% to $3.37M, driven by a $1.1M reduction in R&D costs.
- 9M: Total operating expenses increased 16% to $13.45M. This increase was driven by a $453K loss on the early termination of a vendor agreement (Cell Ready) and higher R&D spend ($9.66M vs $8.38M).
- Capital Raise: The company raised approximately $9.9M in net proceeds during the nine months ended September 30, 2025, via its At-The-Market (ATM) offering agreement, significantly improving liquidity compared to the prior year.
- Share Count: Weighted average shares outstanding increased significantly (from ~8.9M in 2024 to ~16.8M in 2025) due to ATM sales and warrant exercises.
Outlook, Risks, and Management Commentary
- Liquidity & Going Concern: Management states that current cash resources ($18.9M) are sufficient to fund operations through the third quarter of 2026, assuming no additional grant funds are received. The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern without further capital raises.
- Clinical Progress:
- MT-601 (Lymphoma): Phase 1 APOLLO study data showed a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients and 78% in Hodgkin Lymphoma (HL) patients. No dose-limiting toxicities or ICANS observed.
- MT-401 (OTS): First patient treated in the Off-the-Shelf program in October 2025 with encouraging preliminary safety data.
- Manufacturing: Terminated a Master Services Agreement with Cell Ready (related party) in March 2025, incurring a $453K settlement cost. Entered a new Statement of Work with Cellipont Bioservices in June 2025 to support cGMP manufacturing for the APOLLO study.
- Risks:
- Government Shutdown: The filing notes a federal government shutdown as of September 30, 2025, which could delay FDA reviews and NIH grant disbursements.
- Capital Markets: Reliance on equity financing and grants; inability to raise capital could force delays in clinical trials.
Investor Verification Checklist
- Runway Validation: Verify if the $18.9M cash balance is sufficient to fund the planned pivotal lymphoma trial and OTS expansion through Q3 2026 without dilution.
- Grant Receivables: Confirm the collectability of the ~$1.6M in grant income receivables (CPRIT, NIH, FDA) given the noted federal government shutdown.
- Manufacturing Transition: Monitor the technology transfer progress with the new CDMO (Cellipont) to ensure no delays in the APOLLO study scale-up.
- Dilution Impact: Assess the impact of the recent ATM sales (average price $1.48 - $2.87) and outstanding warrants (~7.7M shares) on future share count and per-share value.
- Related Party Transactions: Review the terms of the ongoing license and supply agreements with Baylor College of Medicine (BCM), a significant shareholder and service provider.